Business
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all
About this update from Mustang Bio, Inc.
[{"type":"text","content":"10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose levels, including one patient previously treated with CD19-targeted CAR T-cell therapy Initial data from ongoing multicenter trial expected shortly WORCESTER, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that final data from the follicular lymphoma (“FL”) cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response (“ORR”) and complete response (“CR”) rates and CAR T persistence in FL patients. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”) to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). The final FL cohort results from the Phase 1/2 clinical trial being conducted at Fred Hutch were presented by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutch and University of Washington, at the 17th International Conference on Malignant Lymphoma (“17-ICML”). “MB-106 continues to show promise as a viable treatment option for patients with FL and other B-NHLs, as evidenced by a 95% overall response rate in the FL cohort of the Phase 1/2 clinical trial, including a patient previously treated with a CD19 CAR T-cell therapy who remains in remission,” said Dr. Shadman. “Importantly, MB-106 was infused in an outpatient setting except for the first patient at each dose level, further highlighting the potential of this therapy to fill an unmet need in FL and other B-NHLs. We look forward to the publication of the final data in a peer-reviewed journal in the near future.” A total of 20 patients with relapsed FL with confirmed CD20 expression participated in the study and had day 28 assessment. Median age was 63 years (range: 44 – 81), and median prior lines of treatment was 4 (range: 1 – 12). High-risk f...